CHAMPIONS ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.13 USD | +5.36% |
|
+2.19% | -8.72% |
| 03-15 | Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. | CI |
| 03-13 | Craig-Hallum Downgrades Champions Oncology to Hold From Buy | MT |
Valuation
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 105.5 | 91.77 | 143.7 | 103.9 | 66.71 | 69.74 | - | - |
| Enterprise Value (EV) 1 | 105.5 | 91.77 | 143.7 | 103.9 | 66.71 | 69.74 | 69.74 | 69.74 |
| P/E ratio | 908 x | -45.4 x | 537 x | 192 x | -12.6 x | - | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.9 x | 2.86 x | 3.5 x | 2.11 x | 1.24 x | 1.43 x | 1.3 x | 1.18 x |
| EV / Revenue | 3.9 x | 2.86 x | 3.5 x | 2.11 x | 1.24 x | 1.43 x | 1.3 x | 1.18 x |
| EV / EBITDA | 120 x | -90 x | 94.4 x | 47 x | -30.9 x | -10.6 x | -26.4 x | - |
| EV / FCF | 103 x | 134 x | -29 x | - | 61.6 x | -8.79 x | -9.94 x | -24.4 x |
| FCF Yield | 0.97% | 0.75% | -3.45% | - | 1.62% | -11.4% | -10.1% | -4.1% |
| Price to Book | 57.1 x | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11,615 | 11,888 | 13,390 | 13,522 | 13,559 | 13,594 | - | - |
| Reference price 2 | 9.080 | 7.720 | 10.73 | 7.680 | 4.920 | 5.130 | 5.130 | 5.130 |
| Announcement Date | 19-07-15 | 20-07-27 | 21-07-22 | 22-07-21 | 23-07-24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 27.07 | 32.12 | 41.04 | 49.11 | 53.87 | 48.84 | 53.68 | 59.31 |
| EBITDA 1 | 0.876 | -1.02 | 1.522 | 2.21 | -2.157 | -6.559 | -2.645 | - |
| EBIT 1 | 0.27 | -1.803 | 0.338 | 0.607 | -5.256 | -9.502 | -5.674 | -1.483 |
| Operating Margin | 1% | -5.61% | 0.82% | 1.24% | -9.76% | -19.45% | -10.57% | -2.5% |
| Earnings before Tax (EBT) 1 | 0.231 | -1.845 | 0.409 | 0.583 | -5.267 | -9.53 | -5.654 | - |
| Net income | 0.128 | -1.975 | 0.334 | 0.548 | -5.335 | - | - | - |
| Net margin | 0.47% | -6.15% | 0.81% | 1.12% | -9.9% | - | - | - |
| EPS | 0.0100 | -0.1700 | 0.0200 | 0.0400 | -0.3900 | - | - | - |
| Free Cash Flow 1 | 1.028 | 0.685 | -4.962 | - | 1.083 | -7.93 | -7.015 | -2.86 |
| FCF margin | 3.8% | 2.13% | -12.09% | - | 2.01% | -16.24% | -13.07% | -4.82% |
| FCF Conversion (EBITDA) | 117.35% | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | 803.12% | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 19-07-15 | 20-07-27 | 21-07-22 | 22-07-21 | 23-07-24 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: April | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.79 | 13.19 | 12.88 | 13.74 | 14.28 | 12.77 | 13.07 | 12.56 | 11.57 | 12.02 | 12.69 | 13.1 | 13.32 | 13.53 | 13.72 |
| EBITDA 1 | 0.635 | 1.194 | 0.222 | 0.226 | 0.686 | -1.516 | -1.749 | -1.67 | -1.418 | -1.659 | -1.707 | -0.816 | -0.775 | -0.422 | -0.632 |
| EBIT 1 | 0.263 | 0.83 | -0.311 | -0.284 | 0.007 | -2.458 | -2.521 | -2.552 | -1.955 | -2.577 | -2.418 | -1.567 | -1.476 | -1.273 | -1.358 |
| Operating Margin | 2.23% | 6.29% | -2.42% | -2.07% | 0.05% | -19.24% | -19.29% | -20.32% | -16.89% | -21.44% | -19.05% | -11.96% | -11.08% | -9.41% | -9.9% |
| Earnings before Tax (EBT) 1 | 0.289 | 0.798 | -0.346 | -0.302 | -0.002 | -2.422 | -2.541 | -2.538 | -2.06 | -2.519 | -2.413 | -1.562 | -1.471 | -1.268 | -1.353 |
| Net income | 0.277 | 0.787 | -0.344 | -0.319 | -0.016 | -2.439 | -2.561 | -2.566 | -2.071 | - | - | - | - | - | - |
| Net margin | 2.35% | 5.97% | -2.67% | -2.32% | -0.11% | -19.09% | -19.59% | -20.43% | -17.9% | - | - | - | - | - | - |
| EPS | 0.0200 | 0.0500 | -0.0200 | -0.0200 | - | -0.1800 | -0.1900 | -0.1900 | -0.1500 | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-12-13 | 22-03-15 | 22-07-21 | 22-09-12 | 22-12-13 | 23-03-15 | 23-07-24 | 23-09-13 | 23-12-12 | 24-03-12 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 1.03 | 0.69 | -4.96 | - | 1.08 | -7.93 | -7.02 | -2.86 |
| ROE (net income / shareholders' equity) | 11.4% | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | 1.32% | - | - | - | - | - | - | - |
| Assets | 9.697 | - | - | - | - | - | - | - |
| Book Value Per Share | 0.1600 | - | - | - | - | - | - | - |
| Cash Flow per Share | 0.1300 | 0.2500 | -0.1300 | 0.2200 | -0.1600 | - | - | - |
| Capex 1 | 0.83 | 2.22 | 3.28 | 2.38 | 2.87 | 1.07 | 2.6 | 2.67 |
| Capex / Sales | 3.08% | 6.91% | 7.99% | 4.85% | 5.33% | 2.2% | 4.84% | 4.49% |
| Announcement Date | 19-07-15 | 20-07-27 | 21-07-22 | 22-07-21 | 23-07-24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
5.13
USD
Average target price
6
USD
Spread / Average Target
+16.96%
| 1st Jan change | Capi. | |
|---|---|---|
| -8.72% | 69.74M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- CSBR Stock
- Financials Champions Oncology, Inc.
